Horn & Co houses a ‘dedicated and effective’ practice, best known for handling the full spectrum of transactional issues, including asset purchase agreements and joint ventures, in addition to manufacturing, supply, and distribution agreements. Yuval Horn leads the team, and is known for his extensive expertise in handling multijurisdictional M&A, corporate reorganisations, and public offerings in the US, Europe, and Israel. Corporate finance specialist Keren Kanir represents both public and private companies, and investors on a vast array of issues, including the establishment of funds, data licensing agreements, and private investment rounds led by angel investors and venture capital funds.
Testimonials
Collated independently by Legal 500 research team.
‘Very professional, dedicated and effective.’
Key clients
- Biosight Ltd.
- Panaxia Pharmaceutical Industries Ltd.
Work highlights
- Represented the shareholders of Immunorizon Ltd., a private pharma company, in an acquisition through a share purchase agreement with Purple Biotech Ltd., a clinical-stage company. Immunorizon was purchased for an upfront consideration of $7m, half of which was paid by issuance of shares of the acquirer, which is a dual company traded both in NASDAQ and the Tel-Aviv Stock Exchange. Following the closing, the shareholders of Immunorizon are entitled to receive up to an additional $100m as royalties, milestone payments and exit fees.
- Advised Vascular Biogenics Ltd., an Israeli company traded on the Nsadaq, on its merger with Notable Labs, Inc., a US private company under which, Notable Labs will merge into a wholly owned subsidiary of VBL, with Notable surviving as a wholly owned subsidiary of VBL.